Literature DB >> 9018121

The TEL gene products: nuclear phosphoproteins with DNA binding properties.

H Poirel1, C Oury, C Carron, E Duprez, Y Laabi, A Tsapis, S P Romana, M Mauchauffe, M Le Coniat, R Berger, J Ghysdael, O A Bernard.   

Abstract

The human TEL gene is involved in several 12p13 chromosomal abnormalities present in various human hematological malignancies, the most frequent being the t(12;21)(p13;q22), specific for childhood acute lymphoblastic leukemia. The predicted product of TEL harbours an amino acid region similar to the ETS DNA binding domain. We now report the isolation of the murine TEL cDNA and the characterization of the human TEL proteins. Human and murine TEL proteins are particularly homologous within their aminoterminal regions and their ETS domains. TEL proteins are nuclear and display specific DNA binding activity toward classical ETS binding sites. In addition, we show that TEL mRNAs initiate translation at either of the two first inframe ATGs (codon 1 and 43) to encode 50 kDa and 57 kDa TEL proteins. In vivo, each of these primary translational products is modified by multiple phosphorylation events.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9018121     DOI: 10.1038/sj.onc.1200829

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  27 in total

1.  Tel, a frequent target of leukemic translocations, induces cellular aggregation and influences expression of extracellular matrix components.

Authors:  L Van Rompaey; W Dou; A Buijs; G Grosveld
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

2.  The MN1-TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity.

Authors:  A Buijs; L van Rompaey; A C Molijn; J N Davis; A C Vertegaal; M D Potter; C Adams; S van Baal; E C Zwarthoff; M F Roussel; G C Grosveld
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

3.  Leukemia-related transcription factor TEL is negatively regulated through extracellular signal-regulated kinase-induced phosphorylation.

Authors:  Kazuhiro Maki; Honoka Arai; Kazuo Waga; Ko Sasaki; Fumihiko Nakamura; Yoichi Imai; Mineo Kurokawa; Hisamaru Hirai; Kinuko Mitani
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

4.  Quantification of multiple gene expression in individual cells.

Authors:  António Peixoto; Marta Monteiro; Benedita Rocha; Henrique Veiga-Fernandes
Journal:  Genome Res       Date:  2004-10       Impact factor: 9.043

Review 5.  ETV6 in hematopoiesis and leukemia predisposition.

Authors:  Hanno Hock; Akiko Shimamura
Journal:  Semin Hematol       Date:  2017-04-07       Impact factor: 3.851

6.  TEL/ETV6 binds to corepressor KAP1 via the HLH domain.

Authors:  Yuka Nakamura; Tetsuya Yamagata; Kazuhiro Maki; Ko Sasaki; Issay Kitabayashi; Kinuko Mitani
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

7.  Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors.

Authors:  Peter C Hollenhorst; David A Jones; Barbara J Graves
Journal:  Nucleic Acids Res       Date:  2004-10-21       Impact factor: 16.971

8.  The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion.

Authors:  F Salomon-Nguyen; V Della-Valle; M Mauchauffe; M Busson-Le Coniat; J Ghysdael; R Berger; O A Bernard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

9.  DNA Occupancy of Polymerizing Transcription Factors: A Chemical Model of the ETS Family Factor Yan.

Authors:  C Matthew Hope; Ilaria Rebay; John Reinitz
Journal:  Biophys J       Date:  2017-01-10       Impact factor: 4.033

10.  The acetyltransferase 60 kDa trans-acting regulatory protein of HIV type 1-interacting protein (Tip60) interacts with the translocation E26 transforming-specific leukaemia gene (TEL) and functions as a transcriptional co-repressor.

Authors:  Iver Nordentoft; Poul Jørgensen
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.